Engle Martin & Associates, LLC Announces Acquisition of EIMC, LLC
17.4.2023 15:00:00 EEST | Business Wire | Press release
Engle Martin & Associates, LLC ("Engle Martin"), a market-leading independent loss adjusting and claims management provider, announced today that it has acquired EIMC, LLC (“EIMC”), a leading global provider of ocean marine, risk management, claims investigation, and subrogation services based in Jersey City, New Jersey and London, England.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230417005197/en/
Founded in 1968, EIMC serves clients across the entire marine global supply chain with 50+ years of expertise in providing the full continuum of assessments, risk mitigation, and claim resolution solutions within marine cargo, stock throughout, hull & machinery, and fine art & specie. EIMC operates in 15 office locations strategically positioned in the United States and the United Kingdom. The organization works with a broad group of clients in all major international insurance markets and is also the Lloyd’s Agent for multiple locations in the United States. Since its inception, EIMC has been recognized by major international insurers and numerous insurance associations as a premier provider of marine insurance risk management and claims services.
This acquisition expands Engle Martin’s global footprint and diversifies its service portfolio by providing clients with a full suite of ocean marine services. This acquisition also provides EIMC an extensive back-office infrastructure, innovative technology solutions, and growth opportunities for team members. EIMC has a remarkable history within the maritime community that has resulted in distinctive and long-lasting relationships with its clients and carrier partners. EIMC’s leadership team will remain in place and will maintain operational oversight of their portfolio.
When asked about the acquisition, Jay Campbell, Executive Vice President of Strategy & Organizational Growth of Engle Martin, said “We are excited to continue growing and investing in our business. The acquisition expands our service capabilities in the ocean marine & technical risk services arena with an organization that is well-aligned with our culture and approach to business. We will continue to provide our clients with the same service, quality, and capabilities they have come to expect from our team, with a complementary service that allows us to respond to our customers in a holistic manner.”
Tiina Ruhlandt, Managing Director of EIMC, said “We are delighted that Engle Martin appreciates the value of our organization; and we are confident and excited that our combined expertise will have a positive impact on our continued growth and success. We believe that this partnership is an excellent extension of Engle Martin’s long-term business strategy, and we are thrilled to have a partner who shares our principles and respects the culture which has driven our success.”
About Engle Martin
Engle Martin is a market-leading independent loss adjusting and claims management provider. Engle Martin has a comprehensive business philosophy: to provide the best insurance claim adjustment results in the industry, present the most talented claims professionals, foster an innovative and professional leadership team, and develop client-focused solutions. The firm provides a comprehensive line of service offerings including commercial property, casualty, specialty marine and transportation, appraisal/umpire, specialty audits, carrier outsourcing, and claims management services. For details about industries served and services offered by Engle Martin, visit EngleMartin.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005197/en/
Contact information
Dominique Enriquez
Marketing Director
+1 678.553.3872
denriquez@englemartin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
